Abstract
The last two decades have seen an explosion in our understanding of the clinical nature of narcolepsy and its pathogenesis, fuelling new approaches to potentially effective treatments. It is now recognised that the full narcoleptic syndrome has significant adverse effects on sleep regulation across the full 24-h period and is often associated with clinical features outside the sleep–wake domain. The discovery that most narcoleptic subjects specifically lack a hypothalamic neuropeptide (hypocretin, also called orexin) was a truly original and landmark observation in 1999, greatly furthering our understanding both of the syndrome itself and sleep biology in general. An autoimmune pathophysiology has long been suggested by the tight association with specific histocompatibility antigens and very recently partly confirmed by detailed analysis of T-cell immunological function in affected subjects. Drug treatments remain symptomatic but may soon become more focussed by restoring central hypocretin signalling with replacement therapy. Potentially disease-modifying, immunological approaches have yet to be studied systematically, although the interval between disease onset and development of the full clinical syndrome may be longer than previously appreciated, affording a realistic window of opportunity for limiting neuronal damage in this disabling condition.
Similar content being viewed by others
References
Silber MH, Krahn LE, Olson EJ, Pankratz VS (2002) The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 25:197–202
Ohayon MM, Priest RG, Zulley J et al (2002) Prevalence of narcolepsy symptomology and diagnosis in the European general population. Neurology 58:1826–1833
Thorpy MJ, Krieger AC (2014) Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med 15:502–507
Lin L, Faraco J, Li R et al (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98:365–376
Nishino S, Ripley B, Overeem S et al (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355:39–40
Peyron C, Tighe DK, van der Pol AN et al (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18:9996–10015
Gonzalez JA, Iordanidou P, Strom M et al (2016) Awake dynamics and brain-wide inputs of hypothalamic MCH and orexin networks. Nat Commun 7:11395
Parker JA, Bloom SR (2012) Hypothalamic neuropeptides and the regulation of appetite. Neuropharmacology 63:18–30
De la Herran-Arita AK, Drucker-Colin R (2012) Models for narcolepsy with cataplexy drug discovery. Expert Opin Drug Discov 7:155–164
Pizza F, Franceschini C, Peltola H et al (2015) Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain 136:3787–3795
Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE (2018) The neurobiological basis of narcolepsy. Nat Rev Neurosci. https://doi.org/10.1038/s41583-018-0097-x
Overeem S, Lammers GJ, van Dijk JG (1999) Weak with laughter. Lancet 354:838
van Holst RJ, van der Cruijsen L, van Mierlo P et al (2016) Aberrant food choices after satiation in human orexin-deficient narcolepsy type 1. Sleep 39:1951–1959
Lammers GJ, Pijl H, Iestra J et al (1996) Spontaneous food choice in narcolepsy. Sleep 19:75–76
Schuld A, Hebebrand J, Geller F, Pollmacher T (2000) Increased body-mass index in patients with narcolepsy. Lancer 355:1275
Chabas D, Foulon C, Gonzalez J et al (2007) Eating disorder and metabolism in narcoleptic patients. Sleep 30:1267–1273
Poli F, Pizza F, Mignot E et al (2013) High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy. Sleep 36:175–181
Georgescu D, Zachariou V, Barrot M et al (2003) Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci 23:3106–3111
Sharf R, Sarhan M, Dileone RJ (2008) Orexin mediates the expression of precipitated morphine withdrawal and concurrent activation of the nucleus accumbens shell. Biol Psychiatry 64:175–183
Shoblock JR, Welty N, Alusiio L et al (2011) Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement. Psychpharmacology 215:191–203
Dimitrova A, Fronczek R, van der Ploeg J et al (2011) Reward-seeking behaviour in human narcolepsy. J Clin Sleep Med 7:293–300
Ohayon MM (2013) Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med 14:488–492
The American Academy of Sleep Medicine (2012) The international classification of sleep disorders: diagnostic and coding manual, 3rd edn. AASM, Chicago
Kayabashi T, Sagawa Y, Takemura F et al (2011) The pathophysiologic basis of secondary narcolepsy and hypersomnia. Curr Neurol Neurosci Rep 11:235–241
Wing YK, Chen L, Lam SP et al (2011) Familial aggregation of narcolepsy. Sleep Med 12:947–951
Peyron C, Faraco J, Rogers W et al (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991–997
Taft M, Hor H, Dauvilliers Y et al (2014) DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep 37:19–25
Pelin Z, Guilleminault C, Risch N et al (1998) HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US Modafinil in Narcolepsy Multicenter Study Group. Tissue Antigens 51:96–100
Ollila HM, Ravel JM, Han F et al (2015) HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy. Am J Hum Genet 96:136–146
Han F, Lin L, Warby SC et al (2011) Narcolepsy onset is seasonal and increased following the H1N1 pandemic in China. Ann Neurol 70:410–417
Partinen M, Saarenpaa-Heikkila O, Ilveskoski I et al (2012) Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 7:e33732
Sarkanen TO, Alakuijala APE, Dauvilliers YA, Partinenen MM (2018) Incidence of narcolepsy after H1N1 influenza and vaccinations: systematic review and meta-analysis. Sleep Med Rev 38:177–186
Luo G, Ambati A, Lin L et al (2018) Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy. Proc Natl Acad Sci USA 115:E12323–E12332
Scammell TE (2006) The frustrating and mostly fruitless search for an autoimmune cause of narcolepsy. Sleep 29:633–638
Luo G, Lin L, Jacob L et al (2017) Absence of anti-hypocretin receptor 2 autoantibodies in post pandremix narcolepsy cases. PLoS One 12:e0187305
Liblau RS (2018) Put to sleep by immune cells. Nature 562:46–48
Siebald C, Hansen BE, Wyer JR et al (2004) Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers string susceptibility to narcolepsy. Proc Natl Acad Sci USA 101:1999–2004
Hallmayer J, Faraco J, Lin L et al (2009) Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 41:708–711
Latorre D, Kallweit U, Armentani E et al (2018) T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature 562:63–68
Lopez R, Barateau L, Evangelista E et al (2017) Temporal changes in the cerebrospinal fluid level of hypocretin-1 and histamine in narcolepsy. Sleep. https://doi.org/10.1093/sleep/zsw010
Pizza F, Vandi S, Liguori R et al (2014) Primary progressive narcolepsy type 1: the other side of the coin. Neurology 83:2189–2190
Walker LA, Bourque P, Smith AM, Warman Chardon J (2017) Autosomal dominant cerebellar ataxia, deafness, and narcolepsy (ADCA-DN) associated with progressive cognitive and behavioural deterioration. Neuropsychology 31:292–303
Roth T, Dauvilliers Y, Guinta D et al (2017) Effect of sodium oxybate on disrupted nighttime sleep in patiens with narcolepsy. J Sleep Res 26:407–414
Alshaikh MK, Tricco AC, Tashkandi M et al (2012) Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis. J Clin Sleep Med 15:451–458
Calik MW (2017) Update on the treatment of narcolepsy: clinical efficacy of pitolisant. Nat Sci Sleep 9:127–133
Szakacs Z, Dauvilliers Y, Mikhaylov V et al (2017) Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomized, double-blind, placebo-controlled trial. Lancet Neurol 16:200–207
Abad VC, Guilleminault C (2018) Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea. Expert Rev Respir Med 2:1–13
Irukayama-Tomobe Y, Ogawa Y, Tominaga H et al (2017) Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. Proc Natl Acad Sci USA 30(114):5731–5736
Takenoshita S, Sakai N, Chiba Y et al (2018) An overview of hypocretin based therapy in narcolepsy. Expert Opin Investig Drugs 27:389–406
Nishino S, Sakurai E, Nevsimalova S et al (2009) Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. Sleep 32:175–180
Schone C, Aspergis-Schoute J, Sakurai T et al (2014) Coreleased orexin and glutamate evoke nonredundant spike outputs and computations in histamine neurons. Cell Rep 7:687–704
Reti IM, Reddy R, Worley PF, Baraban JM (2002) Selective expression of Narp, a secreted neuronal pentraxin, in orexin neurons. J Neurochem 82:1561–1565
Chou TC, Lee CE, Lu J et al (2001) Orexin (hypocretin) neurons contain dynorphin. J Neurosci 21:RC168
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The author has no conflicts of interest to declare.
Rights and permissions
About this article
Cite this article
Reading, P.J. Update on narcolepsy. J Neurol 266, 1809–1815 (2019). https://doi.org/10.1007/s00415-019-09310-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-019-09310-3